Search hospitals > Tennessee > Nashville

Monroe Carell Jr. Children's Hospital at Vanderbilt

Claim this profile
Nashville, Tennessee 37212
Global Leader in Adult T-Cell Leukemia/Lymphoma
Global Leader in Post-Implantation Syndrome
Conducts research for Acute Lymphoblastic Leukemia
Conducts research for Infections and Infestations
Conducts research for Lymphoid Hematopoietic Disease
159 reported clinical trials
20 medical researchers
Photo of Monroe Carell Jr. Children's Hospital at Vanderbilt in NashvillePhoto of Monroe Carell Jr. Children's Hospital at Vanderbilt in NashvillePhoto of Monroe Carell Jr. Children's Hospital at Vanderbilt in Nashville

Summary

Monroe Carell Jr. Children's Hospital at Vanderbilt is a medical facility located in Nashville, Tennessee. This center is recognized for care of Adult T-Cell Leukemia/Lymphoma, Post-Implantation Syndrome, Acute Lymphoblastic Leukemia, Infections and Infestations, Lymphoid Hematopoietic Disease and other specialties. Monroe Carell Jr. Children's Hospital at Vanderbilt is involved with conducting 159 clinical trials across 336 conditions. There are 20 research doctors associated with this hospital, such as Carrie Kitko, Devang J. Pastakia, Robert Naftel, MD, and Michael O'Connor, MD.

Area of expertise

1Adult T-Cell Leukemia/Lymphoma
Global Leader
Monroe Carell Jr. Children's Hospital at Vanderbilt has run 16 trials for Adult T-Cell Leukemia/Lymphoma. Some of their research focus areas include:
FLT3 negative
CD19 positive
2Post-Implantation Syndrome
Global Leader
Monroe Carell Jr. Children's Hospital at Vanderbilt has run 14 trials for Post-Implantation Syndrome. Some of their research focus areas include:
GABRA5 positive
GABRG3 positive
UBE3A positive

Top PIs

Clinical Trials running at Monroe Carell Jr. Children's Hospital at Vanderbilt

Asthma
Bronchiolitis
Infections and Infestations
Cystic Fibrosis
Lazy Eye
Birth Defect
Alagille Syndrome
Post-Implantation Syndrome
Hydrocephalus
Angelman Syndrome
Image of trial facility.

Dupilumab

for Asthma

This is a parallel, Phase 3, 2-arm study to evaluate the efficacy and long-term safety of dupilumab treatment in children 2 to \<6 years of age with uncontrolled asthma and/or recurrent severe asthmatic wheeze. The study will be conducted in 2 parts. Part A will be a 52-week, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of dupilumab in children aged 2 to \<6 years old with uncontrolled asthma and/or recurrent severe asthmatic wheeze. At the end of Part A, all eligible participants will be offered participation in Part B, an optional open-label extension phase. Study details include: Part A: The study duration of part A will be up to 68 weeks consisting of a 4-week Screening, a 52week treatment period, and a 12-week post-treatment follow-up period. For participants who will chose to participate in Part B, the study duration will be up to 120 weeks (additional 52-week treatment period). Part B: For participants who will choose to participate in Part B, the study duration will be up to 120 weeks (Part A \[4-week Screening and a 52-week treatment period\] plus additional 52-week treatment period and a 12-week post-treatment follow-up period).
Recruiting1 award Phase 310 criteria
Image of trial facility.

Decision Support

for Lower Respiratory Infections in Children

Eliminating inappropriate antibiotic use in pediatric lower respiratory tract infections (LRTI) is the central focus of this research. LRTIs (pneumonia, bronchiolitis, and infection-related exacerbations of asthma) account for nearly one-third of all emergency department (ED) visits and 40% of all infection-related hospitalizations in US children. LRTIs also account for more antibiotic use in children's hospitals than any other condition, despite most LRTIs being viral in nature. Inappropriate antibiotics are associated with substantial adverse effects. Accordingly, national guidelines strongly discourage routine antibiotic use for bronchiolitis and acute asthma and argue for significantly reducing antibiotic exposure (initiation, spectrum, and duration) in pneumonia. To address the problem of inappropriate antibiotic use, hospital-based antimicrobial stewardship programs (ASPs) are now common nationwide, and these programs have demonstrated effectiveness in some hospital settings. Unfortunately, traditional ASP approaches do not translate well to the fast-paced and unpredictable ED environment, and hospital-based ASP resources are finite and not always immediately available. Clinical decision support (CDS) embedded within the electronic health record (EHR) is a strategy that could address the ED antibiotic stewardship gap. Informed by a deep understanding of the key facilitators and barriers to using CDS to support appropriate antibiotic use in ED and hospital settings, the investigators have developed two stewardship-focused CDS interventions for pediatric LRTI. The overarching goal of this research is to rigorously evaluate the implementation and effectiveness of these CDS tools, alone and in combination, against usual care only in a pragmatic randomized clinical trial at 3 U.S. children's hospitals.
Recruiting1 award N/A2 criteria
Image of trial facility.

Montelukast

for Childhood Asthma

This trial is testing montelukast in children aged 4-12 with severe asthma attacks that don't respond well to standard treatments. Montelukast helps by blocking substances that cause airway inflammation, potentially improving breathing. The study aims to find the right dose that improves asthma symptoms.
Recruiting0 awards Phase 23 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Monroe Carell Jr. Children's Hospital at Vanderbilt?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security